Top section
Top section
◆ The threat of US corporate issuance to European borrowers ◆ The new funding environment for Middle East banks ◆ Reviving UK equity capital markets
Holdings down 16.4% from almost a quarter after institutional bookbuild and off-market buyback deal
Deal multiple times oversubscribed as investors buy into electrification and AI story
More articles
More articles
More articles
-
South Korea’s stock exchange regulator has amended rules for listing on the country’s main board, in an effort to make the process easier and encourage more IPOs on the bourse. -
Alkem Laboratories is set to price its Rp13.5bn ($202.1m) IPO at the top of the range after investors piled into the trade, buoyed by healthy demand for the Indian pharmaceutical sector.
-
Dr Lal Pathlabs has priced its Rp6.4bn ($95.2m) IPO at the upper end of guidance following strong demand from investors.
-
RPC Group, the London-listed plastic products maker, is raising £232.6m in a rights issue to back its acquisition of GCS Group, the manufacturer of lids and dispensers.
-
National Australia Bank has laid out its plans to float its UK mid-sized bank unit CYBG in London early next year.
-
YiChang HEC ChangJiang Pharmaceutical Co has opened books for a float of HK$1.67bn ($215m), kicking off the process with a renowned pharma investor among the cornerstones.
Sub-sections
shared comment list
